Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers

Gynecologic and Obstetric Investigation

Volumn 69, Issue 4, 2010, Pages 270-273

  Stuckey, Ashley ^a,b,c   Dizon, Don ^a,b   Scalia Wilbur, Jennifer ^a   Kent, Jessica ^a   Tejada Berges, Trevor ^a,b   Gass, Jennifer ^a,b   Legare, Robert ^a,b  

^a Breast Health Center Program in Women's Oncology   (Australia)

^b BROWN UNIVERSITY   (United States)

^c Program in Women's Oncology   (United States)

Author keywords

BRCA mutation; Breast cancer; Ovarian cancer; Prophylactic mastectomy; Salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; EMPLOYMENT; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MARRIED WOMAN; MASTECTOMY; MEDICAL DECISION MAKING; MEDICAL HISTORY; OVARY ADENOCARCINOMA; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADOLESCENT; ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; EMPLOYMENT; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; MARITAL STATUS; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PARITY; PATIENT PREFERENCE; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 74249086833     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276573     Document Type: Article

References (9)

1. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-689.
2. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
3. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56: 265-271.
4. Ford D, Easton DF, Bishop DT, et al.: Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-695.
5. Schwartz MD, Lerman C, Brogan B, et al.: Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22: 1823-1829. (Pubitemid 41095172)
6. Weitzel JN, McCaffrey SM, Nedelcu R, et al.: Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003; 138: 1323-1328.
7. Meijers-Heijboer H, Brekelmans CT, Menke- Pluymers M, et al.: Use of genetic testing and prophylactic oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003; 21: 1675-1681.
8. Madalinska JB, Hollenstein J, Bleiker E, et al.: Quality-of-life effects of prophylactic salpingo- oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005; 23: 6890-6898.
9. Uyei A, Peterson S, Erlichman J, et al.: Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing. A single-institution study. Cancer 2006; 107: 2745-2751.